MHQ: Clinical IntelligencePowered by SurvivorNet

Medical History
Clinical Trials

?

Prefer to talk instead of typing?

Answers offered are informational and do not constitute medical advice. Learn more

Medical History

Review your patient’s information.

What is your gender?

What is your age?

Clinical Trials

Clear List

Sign In

Welcome to SN Connect, the medical oncology education platform from SurvivorNet.

Sign Up

After INDIGO’s Strong Results, Experts Say the Future of IDH Inhibition Hinges on Timing, Quality of Life, and Smarter Strategies

ASCO Updates: SUCCESSOR-2 Explores a New Sequencing Strategy After Lenalidomide in Multiple Myeloma

VIKTORIA-1 May Sharpen Post-CDK4/6 Choices in PIK3CA-Mutant HR+ Breast Cancer

Daraxonrasib at ASCO 2026: Phase 3 RASolute 302 Data Arrive, And the Second-Line Paradigm in Metastatic PDAC May Never Look the Same

PROTEUS Final Analysis at ASCO 2026: Perioperative Apalutamide Delivers And The Localized High-Risk Paradigm Shifts

persevERA Breast Cancer Study Keeps Oral ER-Targeting Strategy in Focus Despite Negative Primary Result

ASCO 2026: A Bispecific Antibody Just Cracked One of Lung Cancer's Hardest Problems - OS Data Are In, But The U.S. Question Isn't Answered Yet

MHQ: Clinical Intelligence--AI Powering Faster, Smarter Clinical Decisions

For High-Grade Glioma, Targeted BRAF Inhibitor Plixorafenib Granted FDA Breakthrough Status After Promising Early Trials

From ‘Undruggable’ To Actionable: RAS Inhibitors & A Potential New Era Of Targeted Therapy For Pancreatic Cancer

Expanding the Role of PSMA-Targeted Radioligand Therapy in Prostate Cancer: Early Insights From PSMA Addition and the Evolving Use of Lutetium-177–PSMA (Pluvicto)

LIDERA: The First Oral SERD to Demonstrate a Disease-Free Survival Benefit in Early-Stage HR+ Breast Cancer

The AKT Inhibitor Has Arrived: CAPItello-281 Data Are Practice-Changing for PTEN-Deficient Metastatic Prostate Cancer

After INDIGO’s Strong Results, Experts Say the Future of IDH Inhibition Hinges on Timing, Quality of Life, and Smarter Strategies

Dr Paul Richardson

ASCO Updates: SUCCESSOR-2 Explores a New Sequencing Strategy After Lenalidomide in Multiple Myeloma

VIKTORIA-1 May Sharpen Post-CDK4/6 Choices in PIK3CA-Mutant HR+ Breast Cancer

Daraxonrasib at ASCO 2026: Phase 3 RASolute 302 Data Arrive, And the Second-Line Paradigm in Metastatic PDAC May Never Look the Same

abstract design

PROTEUS Final Analysis at ASCO 2026: Perioperative Apalutamide Delivers And The Localized High-Risk Paradigm Shifts

persevERA Breast Cancer Study Keeps Oral ER-Targeting Strategy in Focus Despite Negative Primary Result

ASCO 2026: A Bispecific Antibody Just Cracked One of Lung Cancer's Hardest Problems - OS Data Are In, But The U.S. Question Isn't Answered Yet

MHQ: Clinical Intelligence--AI Powering Faster, Smarter Clinical Decisions

For High-Grade Glioma, Targeted BRAF Inhibitor Plixorafenib Granted FDA Breakthrough Status After Promising Early Trials

From ‘Undruggable’ To Actionable: RAS Inhibitors & A Potential New Era Of Targeted Therapy For Pancreatic Cancer

Expanding the Role of PSMA-Targeted Radioligand Therapy in Prostate Cancer: Early Insights From PSMA Addition and the Evolving Use of Lutetium-177–PSMA (Pluvicto)

LIDERA: The First Oral SERD to Demonstrate a Disease-Free Survival Benefit in Early-Stage HR+ Breast Cancer

The AKT Inhibitor Has Arrived: CAPItello-281 Data Are Practice-Changing for PTEN-Deficient Metastatic Prostate Cancer

MHQ: Clinical Intelligence

Powered by SurvivorNet

Fast, structured answers grounded in guidelines and peer-reviewed research.

What doctors are asking:

Write Patient Take Home Instructions

Ask about treatment alternatives

Find a clinical trial for your patient

Double check data

PROTEUS Final Analysis at ASCO 2026: Perioperative Apalutamide Delivers And The Localized High-Risk Paradigm Shifts

Daraxonrasib at ASCO 2026: Phase 3 RASolute 302 Data Arrive, And the Second-Line Paradigm in Metastatic PDAC May Never Look the Same

ASCO 2026: A Bispecific Antibody Just Cracked One of Lung Cancer's Hardest Problems - OS Data Are In, But The U.S. Question Isn't Answered Yet

After INDIGO’s Strong Results, Experts Say the Future of IDH Inhibition Hinges on Timing, Quality of Life, and Smarter Strategies

VIKTORIA-1 May Sharpen Post-CDK4/6 Choices in PIK3CA-Mutant HR+ Breast Cancer

ASCO Updates: SUCCESSOR-2 Explores a New Sequencing Strategy After Lenalidomide in Multiple Myeloma

Giredestrant + Everolimus After CDK4/6 Inhibitors: Clinical Significance of the evERA Phase 3 Trial

What The Approval Of Enhertu + Pertuzumab Means - Your Colleagues On How The Combination Will Change Practice

FDA Approval For Imlunestrant: Principal Investigator Dr. Jhaveri On The Practice Changing Impact For Advanced ER+/HER2- Breast Cancer Patients

Jaypirca: A Promising Therapy Against Chronic Lymphocytic Leukemia

"A Home Run" For Myeloma: What's Next After The MajesTEC-3 Practice-Changing Results For Relapsed/Refractory Multiple Myeloma

A Paradigm Shift in CAR-T: inMMyCAR Trial

ASTRO 2025 Event: The New Era In Glioma Treatment, Racing To Understand Targeted Therapy & Making Better Decisions For Patients

Oncologists Want Shared Decision Making, So Let's Involve Patients In Critical Education

Vorasidenib and the Changing Care of IDH-Mutant Grade 2 Glioma

How to Find the Right Therapist When You Feel Burned Out -- Advice from a Clinical Psychologist

Staying Connected & Sharing Knowledge: How Community Doctors Can Stay on Top of the Latest in CLL Research

Dr. Bobby Mukkamala's 3 Things Physicians Should Know About Shared Decision-Making With Glioma Patients

Elahere: A Practice-Changing Option for Platinum-Resistant, FRα-Positive Ovarian Cancer

How Will Federal Budget Cuts Affect The Future Of Cancer Research?

Systemic Therapy for Advanced Gastric Cancer: Current Approaches and Emerging Strategies

The Controversy Around Radiation Oncologists, Medical Oncologists & the Use of Vorasidenib for Gliomas

Natural Killer Cells: Is This The Next Generation of Immunotherapy? Understanding The FDA Approval in Bladder Cancer

When to Order Immunohistochemistry Testing: With Tailored Therapies for HER2-Positive Cancers, IHC is More Relevant for More Patients

Yale’s Chief of Breast Oncology Shares Risk Stratification & Recommendations for CDK4/6 Inhibitors

Criteria and Considerations for Using Newly FDA-Approved Lifileucel in Advanced Melanoma

Research Shows the Best Way to Discuss Clinical Trials With Patients & Boost Trust, Confidence

Integrating Genetic Testing and PARP Inhibitors in Prostate Cancer Management

Treating Prostate Cancer: The Value Of A Team Approach

For HR+/HER2- Early-Stage Breast Cancer at Increased Risk of Recurrence, Kisqali Has Benefits: Study

A Powerful Tool: Integrating Venetoclax into CLL Management Improves Survival

Oncologists Weigh in on Optimal Use of CDK 4/6 Inhibitors as Adjuvant Therapy in Early Breast Cancer

Imfinzi Improves Overall & Progression-Free Survival for Patients With Limited-Stage Small Cell Lung Cancer

Balversa's FDA Approval Means a New, Practice-Changing Option for FGFR-Positive Bladder Cancer

Unprecedented Progression-Free Survival for ALK-Positive Non-Small Cell Lung Cancer Using Lorbrena — What the New Research Means for Patients

Physicians Advised to Consider Rybrevant for EGFR Mutation-Positive NSCLC, Following FDA Approval

For Women With Heavily-Treated Triple-Negative or HR+, HER2- Metastatic Breast Cancer, Enfortumab Vedotin (Padcev) Shows Some Anti-Tumor Activity

Understanding Pluvicto (Lutetium-177) and PSMA PET Scans in Prostate Cancer Treatment

Elahere for Ovarian Cancer: Prevention, Detection & Management of Ocular Adverse Events

Nearly 50% Skip Prescribed Breast Cancer Meds — Physicians Should Focus on Education & Cutting Costs

New ASCO Guidelines Offer a Practice-Changing Approach for PIK3CA/AKT1/PTEN Metastatic Breast Cancer

Study: Physicians Should Prioritize Weight Management in Breast Cancer Care to Boost Survival Rates

Why Physicians Should Prioritize Emotional Wellbeing

The issue of burnout has long plagued physicians given the many hours of physically and mentally draining work. But with the recent Covid pandemic and the resulting changes to the industry, the demands on doctors is even higher — and many may be experiencing profession-related mental health issues.

Now more than ever, it’s important to pay attention to the idea of compassion fatigue, says Dr. Marianna Strongin, a licensed clinical psychologist and founder of Strong in Therapy, her Manhattan-based private practice.

Close the Gap 2024 - Addressing Disparities in Cancer Care & Improving Outcomes for Patients

Community Engagement & Resources are Key to ‘Closing the Gap’ on Racial Disparities in Cancer Care

Meeting the Needs of Black Caregivers